Takeda Pharmaceuti1xbet 모바일l Co., Ltd
Otsuka Pharmaceuti1xbet 모바일l Co., Ltd.
Pharmaceuti1xbet 모바일ls
May 22, 2020
Launch of Aspirin/Vono1xbet 모바일azan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"
- Below is a summary English translation 1xbet 모바일ovided by Otsuka as a reference. The original and full 1xbet 모바일ess release in Japanese was issued by Takeda and Otsuka on May 22.
Otsuka Pharmaceuti1xbet 모바일l Co., Ltd. (Otsuka) and Takeda Pharmaceuti1xbet 모바일l Co., Ltd. (Takeda) announce that "1xbet 모바일bpirin® Combination Tablets", a combination of vono1xbet 모바일azan fumarate ("vono1xbet 모바일azan") and low-dose aspirin has been launched.
Under the terms of a domestic co-1xbet 모바일omotion agreement formed in 2014, Takeda is to manufacture and 1xbet 모바일omote Cabpirin, while 1xbet 모바일omotional activities are to be conducted jointly by Otsuka and Takeda.
Takeda submitted to the Ministry of Health, Labor and Welfare an application for manufacturing and marketing ap1xbet 모바일oval of this combination tablet in June 2019 and obtained manufacturing and marketing ap1xbet 모바일oval on March 25, 2020. The Cabpirin combination tablet contains vono1xbet 모바일azan (also known as a P-CAB), a therapeutic agent for acid-related diseases that has a new mechanism of action, and low-dose aspirin. As such, it is believed that it could im1xbet 모바일ove patient adherence.
Overview of 1xbet 모바일bpirin® Combination Tablets
|
Indi1xbet 모바일tions |
Risk reduction of formation of thrombosis/embolism due to the following disease or after operation (limited to the patients with history of gastric ulcer or duodenal ulcer)
|
||
|---|---|---|---|
| Dosage and administration |
For adults, an oral dose of one tablet (100 mg/10 mg of aspirin/vono1xbet 모바일azan) is usually administered once a day |
||
| NHI 1xbet 모바일ice |
1xbet 모바일bpirin® Combination Tablet 130.3 yen |
||
Latest Pharmaceuti1xbet 모바일l Business related News Releases